Opinion: Peer review could help smoke out the next Theranos

The insidious problem with health care unicorns is not one-off, ripe-for-cinema scandal — think Theranos. It is the absence of credible scientific evidence.
Source: APStock

Over a 25-month period, the startup Theranos plummeted from the heights of biotech, with a valuation of $9 billion and a fawning profile in the New Yorker’s “Annals of Innovation” in December 2014, to thanatos (death) when the company shuttered its final laboratory in January 2017. By early 2018, joint investigations by the Securities and Exchange Commission and the Food and Drug Administration, impending bankruptcy, mass layoffs, and fraud charges against the company’s enigmatic founder, Elizabeth Holmes, finished off the so-called unicorn.

Not long after the sentinel New Yorker profile appeared, one of us (J.P.A.I.) about Theranos’ operation in a JAMA Viewpoint. One major concern was that the company hadn’t presented a shred of

You're reading a preview, sign up to read more.

More from STAT

STAT3 min readScience
Inspired By Breath Strips, Scientists Break Away From Needing A ‘Cold Chain’ To Deliver Vaccines
Most vaccines must be kept cold to be effective. Researchers have developed a workaround for delivery to hotter climates — inspired by Listerine breath strips.
STAT5 min readPolitics
Opinion: Ignoring Evidence Begot Medicare’s Dangerous Hospital Readmissions Penalty
If health policies should be shown to be safe and effective before implementation, then risky programs like the Hospital Readmissions Reduction Program should be terminated.
STAT3 min readPolitics
Opinion: Vaccinations Will Take A Hit If The Trump Administration Topples The Affordable Care Act
Immunizations are vital to the public's health. Scrapping the Affordable Care Act, which requires insurers to cover recommended vaccinations, would reduce vaccination rates and threaten herd immunity.